primary Age, baseline QoL and chemotherapy administration influence the degree of change in QoL.
First, samples from included twin studies differed in their age, baseline values, PA interventions, and diet interventions.
Other predisposing factors are: age, baseline muscle function, nutritional status, comorbidities (COPD, renal and heart disease, cancer) [22, 23].
After accounting for age, baseline 6MWD, and steroid use, four latent trajectory classes were identified as explaining 3-year 6MWD outcomes significantly better than a single average trajectory.
In the Scottish study, significant predictors for eGFR decline included age, baseline eGFR, comorbidities, co-prescriptions of nephrotoxic drugs, and episodes of lithium toxicity (Clos et al. 2015).
The characteristics of the included twin and family studies, including sample size, age, baseline PA status, and PA intervention are described in Tables 2 and 3.
Twin studies differed in sample age, baseline values, and PA intervention, although the exclusion of any one study did not affect the results.
Differences between groups after 4 months of DHA supplementation or placebo administration were determined by analysis of variance, controlling for age, baseline value of each outcome variable, ethnicity, and ADHD subtype.
At baseline, factors that were significant between the three groups are age, baseline VL (p<0.05).
Change in weight was adjusted for age, baseline weight and ethnicity.
Age, baseline lung function, AR, and change in BMI were included in the final regression analyses.
